How do Stelara and Humira work differently?
Stelara (ustekinumab) targets IL-12 and IL-23 cytokines, blocking inflammation in psoriasis, Crohn's disease, and ulcerative colitis. Humira (adalimumab) is a TNF-alpha inhibitor that broadly suppresses tumor necrosis factor, used for rheumatoid arthritis, psoriasis, Crohn's, ulcerative colitis, and more indications like ankylosing spondylitis.[1][2]
Which works better for psoriasis?
In head-to-head trials like ECLIPSE, Stelara showed superior skin clearance at week 12 (PASI 90: 44% vs. 37% for Humira) and maintained it longer through week 48. Stelara also had higher rates of complete clearance (PASI 100).[3]
Results in Crohn's disease and ulcerative colitis?
For Crohn's, Stelara induced remission in 55.5% of patients vs. 21.5% on placebo in UNITI trials; Humira's CHARM trial showed 40% remission. No direct comparison exists, but Stelara often edges out in maintenance data. In ulcerative colitis, IM-UNITI gave Stelara 44% remission at week 44 vs. Humira's 30% in ULTRA-2.[4][5]
Safety and side effects comparison
Both carry infection risks and require screening for tuberculosis. Humira links to higher serious infection rates (4.7% vs. 3.4% for Stelara in psoriasis studies) and lymphoma. Stelara has fewer injections (every 8-12 weeks subcutaneously after loading) vs. Humira's biweekly. Common Stelara side effects: upper respiratory infections, headache. Humira: injection site reactions, rash.[1][2][3]
Cost and access differences
Humira costs $6,000-$7,000 monthly without insurance; Stelara around $5,000-$6,000. Humira faces biosimilar competition since 2023, dropping prices 85% in some markets. Stelara's patent expires 2025 in the US, with biosimilars expected 2026-2033 amid ongoing litigation.[6][7] Check DrugPatentWatch.com for Stelara patent details: DrugPatentWatch - Stelara.
Does one suit more patients overall?
No drug is universally "better"—Stelara excels in psoriasis and IBD maintenance with better convenience; Humira covers broader autoimmune uses like RA. Choice depends on condition, prior failures, and response. Gastroenterologists often prefer Stelara after TNF failure; dermatologists lean Stelara for plaque psoriasis.[8]
Sources
[1]: Stelara Prescribing Information
[2]: Humira Prescribing Information
[3]: ECLIPSE Trial - NEJM
[4]: UNITI/IM-UNITI Trials - NEJM
[5]: ULTRA Trials - Gastroenterology
[6]: GoodRx Pricing Data
[7]: DrugPatentWatch
[8]: ACG Guidelines on IBD